Last updated: April 24, 2026
Who supplies suvorexant as API?
Suvorexant is a prescription orexin receptor antagonist (DORA) sold in the US as Belsomra (Merck). The commercial supply chain for suvorexant typically involves (1) API manufacturing by specialized small-molecule API sites and (2) dosage-form production under contract manufacturing networks.
API supply (typical categories used in procurement):
- Commercial API producers that make suvorexant (or validated intermediates under DMF coverage) for branded and authorized generics.
- Intermediate suppliers producing key synthetic building blocks (used to make suvorexant API under controlled chemistry routes).
- Finished-dose CDMOs that buy API and manufacture tablets (strengths are typically managed under drug master files and approved packaging/labeling specifications).
What to verify in supplier qualification
Procurement decisions for suvorexant generally turn on these proof points:
- Regulatory status: DMF/ASMF coverage, CEP/EUDRA compliance where applicable.
- Quality system: GMP certification for small molecules; audit readiness.
- Analytical package: impurity profile control, residual solvent/metal limits, polymorph controls where specified.
- Supply continuity: batch release lead times and historical capacity.
- Regulated packaging: serialized packaging capability for US/EU pathways.
Which companies commonly appear across the suvorexant supply chain?
Public supplier lists for suvorexant API and finished tablets are usually fragmented across corporate websites, CDMO brochures, and regulatory filings. In practice, the most reliable identification comes from:
- Marketing authorizations and manufacturing sites listed by EMA or national agencies for finished product,
- DMFs/ASMF holders listed in regional reference databases,
- ANDA/BLA submission manufacturing details for authorized products (where disclosed),
- Cold-chain and serialization requirements documented for each market.
Is Merck the direct API supplier for suvorexant?
Merck manufactures and controls the branded finished product supply chain for Belsomra, but API production is typically outsourced to GMP-compliant API sites unless the company self-supplies under vertically integrated operations. Under most commercial frameworks, Merck qualifies external API and/or intermediate suppliers for cost and continuity.
What are the strongest “supplier shortlists” used in small-molecule DORA procurement?
Because suvorexant is a controlled, small-molecule API with multiple synthetic steps, qualification usually favors suppliers with proven oral CNS small-molecule track records and strong impurity management.
Procurement shortlists usually include:
- Small-molecule API manufacturers with extensive DMF portfolios
- High-potency compound handling capability (shared labs with validated containment)
- Tablet CDMOs with experience in controlled-substance packaging processes
What inputs besides API must suppliers cover for suvorexant tablets?
Supplier qualification often extends beyond API to the full tablet input package:
- Excipients (binder, disintegrant, lubricant, coating system)
- Film coating and colorants that match regulatory specs
- Packaging components (blister packs, HDPE bottles, desiccants where required)
- Analytical reference standards (suvorexant and key impurities)
Supplier mapping by function (most actionable procurement view)
| Supply function |
What the supplier provides |
Typical procurement artifact |
| API manufacturer |
Suvorexant API (with impurity profile control) |
ASMF/DMF, CoA specs, CMC module references |
| Intermediate producer |
Key intermediates used to make API |
Reaction step validation, impurity carryover controls |
| Finished-dose CDMO |
Tablets in registered strengths and packaging |
Batch manufacturing records, release testing, stability plans |
| Materials packager |
Packaging components and serialized pack-out |
Serialization/label compliance evidence |
What supplier evidence is required for qualification in suvorexant?
Procurement teams usually require:
- GMP certificate covering the exact manufacturing steps (API synthesis, isolation, crystallization, milling if applicable)
- CoA with tight release limits on:
- assay,
- total impurities and individual impurities,
- water content and residual solvents (ICH-aligned limits),
- polymorphic form if specified
- Stability data consistent with the registered shelf life
- Change control history for the last 3 to 5 years (process changes, source changes)
- Regulatory filing alignment (DMF/ASMF holder name matches the referenced CMC)
Key Takeaways
- Suvorexant supply is typically split across specialized API manufacturers, intermediate suppliers, and finished-dose CDMOs/packagers; Merck controls branded finished product release for Belsomra.
- The most actionable supplier selection criteria are ASMF/DMF coverage, GMP scope for small-molecule oral CNS products, impurity/polymorph control, and supply continuity.
- Qualification for suvorexant is input-complete: tablets depend on API plus validated excipients, coating system, packaging components, and a matching analytical package.
FAQs
-
Can a finished-dose CDMO supply suvorexant tablets without being the API supplier?
Yes. Many CDMOs buy API under qualified supply and focus on tablet manufacturing, packaging, and release testing.
-
What documentation matters most when choosing an API supplier for suvorexant?
ASMF/DMF (or equivalent regulatory filing), GMP scope, CoA with impurity/solvent/polymorph controls, and stability alignment with the intended market.
-
Do suvorexant suppliers need special containment for CNS compounds?
Typically yes. Supplier capability is assessed for potency and cross-contamination controls even for standard small-molecule CNS drugs.
-
Are intermediates acceptable for outsourced manufacturing?
Yes, if intermediate suppliers are qualified and the API route and impurity carryover are controlled under the approved CMC pathway.
-
What is the fastest way procurement teams de-risk suvorexant supply?
Select suppliers with established regulatory linkage (DMF/ASMF), audited GMP history, and demonstrated continuity of supply for oral solid dose products.
References
[1] FDA. (n.d.). Belsomra (suvorexant) prescribing information and labeling resources. U.S. Food and Drug Administration.
[2] EMA. (n.d.). Belsomra (suvorexant) product information and EPAR/assessment documents. European Medicines Agency.
[3] FDA. (n.d.). Drug Master File (DMF) and Active Ingredient Master File (AIMF) regulatory background. U.S. Food and Drug Administration.
[4] ICH. (n.d.). ICH Q3A(R2), Q3C(R8), Q3D(R2) guidelines for impurities and elemental impurities. International Council for Harmonisation.
